Company Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
Its transforming growth factor beta (TGFβ) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor.
The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia.
Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Country | United States |
Founded | 2012 |
IPO Date | May 24, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 128 |
CEO | Jay Backstrom |
Contact Details
Address: 301 Binney Street, 3rd Floor Cambridge, Massachusetts 02142 United States | |
Phone | 857 259 3860 |
Website | scholarrock.com |
Stock Details
Ticker Symbol | SRRK |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001727196 |
CUSIP Number | 80706P103 |
ISIN Number | US80706P1030 |
Employer ID | 82-3750435 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Jay Thomas Backstrom M.D., M.P.H. | President, Chief Executive Officer and Director |
Edward H. Myles MBA | Senior Advisor |
Tracey M. Sacco M.B.A. | Chief Commercial Officer |
Ryan Iarrobino | Senior Vice President of Clinical Development and Operations |
Dr. Jing L. Marantz M.B.A., M.D., Ph.D. | Chief Medical Officer |
Beth Shafer Ph.D. | Chief Business Officer |
Lisa Wyman | Chief Technical and Quality Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 24, 2025 | 144 | Filing |
Mar 21, 2025 | 8-K | Current Report |
Mar 17, 2025 | 144 | Filing |
Mar 10, 2025 | 144 | Filing |
Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
Feb 27, 2025 | 10-K | Annual Report |
Feb 27, 2025 | 8-K | Current Report |
Feb 19, 2025 | 144 | Filing |
Feb 14, 2025 | SCHEDULE 13G/A | Filing |
Feb 12, 2025 | SCHEDULE 13G/A | Filing |